Montes Archimedes Acquisition Corp.
MAAC
NASDAQ Capital Market9.35
USD
-0.54
- -
CIK
0001819263
ISIN
US6126571065
CUSIP
612657106
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
-10.10
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- James C. Momtazee
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 724 Oak Grove Menlo Park CA United States of America
- IPO Date
- Dec 3, 2020
- CIK
- 0001819263
- Similar Companies
- Business
- Montes Archimedes Acquisition Corp. (NASDAQ: MAAC) operates as a blank check company, or special purpose acquisition company (SPAC), whose principal business is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar initial business combination with one or more businesses or entities, with an initial focus on the health care ecosystem encompassing technology-enabled services, biopharmaceuticals, pharmaceutical value chain, medical devices, diagnostics, providers, digital health, and consumer health; it generates no operating revenue and maintains no proprietary products or services beyond its standard SPAC structure including units, redeemable Class A common stock, and warrants exercisable at $11.50 per share. Sponsored by Patient Square Capital LLC and founded in July 2020 with headquarters in Menlo Park, California, the company completed a $400 million initial public offering in October 2020 underwritten by Citigroup and Jefferies, depositing proceeds into trust for deployment toward a target acquisition within a 24-month period extendable under certain conditions, while its initial stockholders hold founder shares convertible to Class A upon combination and private placement warrants purchased concurrently at $1.00 each. The company announced a definitive business combination agreement with Roivant Sciences Ltd. in May 2021, valuing the biopharmaceutical holding company at $7.3 billion and providing up to $611 million in gross proceeds including trust assets and a $200 million PIPE from investors such as Fidelity Management and SoftBank; shareholder approval followed in September 2021 with closing on October 1, 2021, after which Montes Archimedes Acquisition Corp. completed its purpose, delisted its MAAC ticker, and transitioned as Roivant Sciences trades under ROIV on Nasdaq with no further SPAC operations, recent funding rounds, acquisitions, product launches, or strategic shifts reported for the legacy entity as of late 2025.
Roivant Provides Corporate Updates
2 Best Biotech Stocks to Buy Now
'SPACs Attack' Recap: Looking Back At 5 SPAC Deals, Rumors And Top Headlines
Roivant Sciences Gets SPAC Deal: What To Expect From This BioPharma, Health Technology Company